Skip to main content
OpenTrials
Completed

NCT Number: NCT03329651

The Interaction Between Metformin and Acute Exercise

Physical activity is a first line treatment for patients with type 2 diabetes (T2D), however, the vast majority of patients with T2D do not achieve satisfying glycemic control with physical activity alone, which is why pharmacological treatment with metformin is most often initiated.

It is known that metformin and exercise both activates 5' adenosine monophosphate-activated protein kinase (AMPK) in skeletal muscle and liver, and the activation of AMPK results in many different metabolic effects, including improvements in glycemic control. Because of this similarity in mechanism of action, an interaction between metformin and exercise is plausible, but knowledge in the area is sparse. Thus, the aim of this study is to assess the effects of acute physical activity with and without concomitant metformin treatment, in order to investigate whether an interaction between the two occur.

Subjects with impaired glucose tolerance will be randomized (1:1) to metformin/placebo treatment in a double-blinded way. Following a treatment run-in period of 17 days, two experimental days (one with acute exercise and one without acute exercise), separated by one week, will be performed in each subject.

This registration concerns a sub-study of another study which has previously been registrered at ClinicalTrials.gov (Unique Protocol ID: H-17012307). The specific outcomes in this registration have not previously been registered.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Center for aktiv sundhed

Copenhagen, Copenhagen N, 2200, Denmark

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Glucose-lowering-medication naïve T2D and/or subjects with impaired glucose tolerance defined as: 2-h plasma glucose (PG) in the 75-g OGTT (7.8-11.0 mmol/L) and/or HbA1c (39-47 mmol/mol)
  • Caucasian
  • BMI > 25 but < 40 kg/m2
  • Low to moderate physically active (≤90 min of structured physical activity/week)

Exclusion criteria

  • Pregnancy
  • Smoking
  • Glucose-lowering treatment
  • Treatment with steroids and other immunomodulating drugs
  • Contraindication to increased levels of physical activity
  • Liver disease (ALAT elevated more than 3 times above upper normal limit, or reduced levels of the liver function markers albumin and KF II+VII+X)
  • Renal insufficiency (eGFR<60 ml/min)
  • Prior history of lactic acidosis
  • HbA1c >55 mmol/mol and/or 2-hPG in the 75-g OGTT > 15 mmol/L

Treatment and study plan

Metformin treatment

Drug

Daily treatment with metformin tablets for 24 days according to the following scheme:

Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-24: Metformin tablet 1000 mg x 2

placebo treatment

Drug

Daily treatment with placebo tablets for 24 days according to the following scheme:

Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-24: Placebo tablet 1000 mg x 2

Primary outcomes

  1. Difference in postprandial glycemic control as assessed by mean blood glucose concentration during a 4 hour mixed-meal tolerance test

    Time frame: Day 17 (no acute exercise [control day]) and 24 (following an acute exercise bout)

Secondary outcomes

  1. Difference in endogenous glucose production as assessed by rate of infused glucose tracer appearance in blood

    Time frame: Day 17 (no acute exercise [control day]) and 24 (following an acute exercise bout)

  2. Difference in exogenous glucose uptake as assessed by rate of ingested glucose tracer appearance in blood

    Time frame: Day 17 (no acute exercise [control day]) and 24 (following an acute exercise bout)

  3. Difference in peripheral glucose uptake as assessed by rate of glucose disappearance from blood

    Time frame: Day 17 (no acute exercise [control day]) and 24 (following an acute exercise bout)

Sponsors and collaborators

Lead sponsor

Kristian Karstoft

Other

Collaborators

  • University of Copenhagen

Registry information

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Nov 6, 2017
Registry last updated
Nov 9, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.